Pharmaceuticals

The EspeRare Foundation and Pierre Fabre join forces to develop and market a pioneering treatment for XLHED, a dermatologic-related rare genetic disease that requires prenatal therapeutic intervention

GENEVA and CASTRES , France, Dec. 14, 2020 /PRNewswire/ -- The EspeRare Foundation and the Pierre Fabre group announced today that they have entered into a license and development collaboration agreement for the development and commercialization of ER-004, a prenatal treatment for XLHED (X-linked...

2020-12-14 09:00 2191

Gannex Received U.S. FDA Fast Track Designation for Its NASH Drug Candidate ASC42,an FXR Agonist

SHANGHAI, Dec. 14, 2020 /PRNewswire/ -- Gannex, a wholly owned company of Ascletis Pharma Inc. (HKEX:1672) and fully dedicated to the R&D and commercialization of new drugs in the field of NASH, announced today that it received Fast Track designation from the U.S. Food and Drug Administration (F...

2020-12-14 08:30 3484
1 ... 184185186187188

Week's Top Stories